VMD's Q2 2021: Outlook Remains BrightOn top of the excellent Q2 results, the significant gross margin expansion on a YoY basis, profitability, positive operating cash flow, positive free cash flow and the increase in NET CASH position on a sequential basis, the outlook is bright, as quoted from the quarterly report:
"I am extremely pleased with our Company’s ability to grow our active patient count across all of our major product lines during the current quarter,” said Casey Hoyt, Viemed's CEO. “We have once again posted extremely strong financial results, and our adherence to always putting the patient first continues to drive strong growth trends throughout the country. We continue to see treating respiratory patients in the home as a major growth segment and are seeing new patient onboardings increase as we continue to navigate through the pandemic.”